AU2017281222B2 - Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof - Google Patents

Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof Download PDF

Info

Publication number
AU2017281222B2
AU2017281222B2 AU2017281222A AU2017281222A AU2017281222B2 AU 2017281222 B2 AU2017281222 B2 AU 2017281222B2 AU 2017281222 A AU2017281222 A AU 2017281222A AU 2017281222 A AU2017281222 A AU 2017281222A AU 2017281222 B2 AU2017281222 B2 AU 2017281222B2
Authority
AU
Australia
Prior art keywords
hgnc
compound
mapk
disease
acc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281222A
Other languages
English (en)
Other versions
AU2017281222A1 (en
Inventor
Jeffrey HASDAY
Alexander Mackerell
Paul Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Office of General Counsel of VA
Original Assignee
University of Maryland Baltimore
US Department of Veterans Affairs
Office of General Counsel of VA
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, US Department of Veterans Affairs, Office of General Counsel of VA, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of AU2017281222A1 publication Critical patent/AU2017281222A1/en
Application granted granted Critical
Publication of AU2017281222B2 publication Critical patent/AU2017281222B2/en
Priority to AU2022218616A priority Critical patent/AU2022218616B2/en
Priority to AU2024202879A priority patent/AU2024202879B2/en
Priority to AU2025259977A priority patent/AU2025259977A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017281222A 2016-06-23 2017-06-22 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof Active AU2017281222B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2022218616A AU2022218616B2 (en) 2016-06-23 2022-08-19 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2024202879A AU2024202879B2 (en) 2016-06-23 2024-05-01 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2025259977A AU2025259977A1 (en) 2016-06-23 2025-10-31 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662353856P 2016-06-23 2016-06-23
US62/353,856 2016-06-23
US201762469913P 2017-03-10 2017-03-10
US62/469,913 2017-03-10
PCT/US2017/038697 WO2017223284A1 (en) 2016-06-23 2017-06-22 NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022218616A Division AU2022218616B2 (en) 2016-06-23 2022-08-19 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017281222A1 AU2017281222A1 (en) 2019-01-24
AU2017281222B2 true AU2017281222B2 (en) 2022-06-16

Family

ID=60784745

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017281222A Active AU2017281222B2 (en) 2016-06-23 2017-06-22 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2022218616A Active AU2022218616B2 (en) 2016-06-23 2022-08-19 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2024202879A Active AU2024202879B2 (en) 2016-06-23 2024-05-01 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2025259977A Pending AU2025259977A1 (en) 2016-06-23 2025-10-31 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2022218616A Active AU2022218616B2 (en) 2016-06-23 2022-08-19 Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2024202879A Active AU2024202879B2 (en) 2016-06-23 2024-05-01 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
AU2025259977A Pending AU2025259977A1 (en) 2016-06-23 2025-10-31 Non-catalytic substrate-selective P38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof

Country Status (6)

Country Link
US (5) US20190151324A1 (enExample)
EP (1) EP3474835B1 (enExample)
JP (2) JP7013453B2 (enExample)
CN (2) CN109640970B (enExample)
AU (4) AU2017281222B2 (enExample)
WO (1) WO2017223284A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3474835B1 (en) 2016-06-23 2023-07-05 University of Maryland, Baltimore Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
EP3890733B1 (en) 2018-12-07 2025-04-16 University of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021236449A1 (en) * 2020-05-18 2021-11-25 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
IL302235A (en) 2020-10-29 2023-06-01 Gen1E Lifesciences Inc 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide dihydrochloride dihydrate crystalline
JP7659650B2 (ja) 2021-03-23 2025-04-09 ジーニー ライフサイエンシズ インコーポレイテッド 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
WO2023004438A2 (en) * 2021-07-22 2023-01-26 The General Hospital Corporation Fret-based assays

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066616A1 (en) * 2005-03-29 2007-03-22 Paul Shapiro Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR96352E (fr) 1967-12-29 1972-06-16 Science Union & Cie Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
DE19801646A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
PT1537116E (pt) 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1597259B1 (de) 2003-02-13 2008-04-30 Sanofi-Aventis Deutschland GmbH Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7297817B2 (en) 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
JP2007532615A (ja) 2004-04-13 2007-11-15 アステックス、セラピューティックス、リミテッド 医薬化合物
TW200904421A (en) * 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
ES2427892T3 (es) 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
EP2355826A1 (en) 2008-11-07 2011-08-17 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
WO2010082912A1 (en) * 2009-01-15 2010-07-22 Avalon Pharmaceuticals Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
HK1217687A1 (zh) 2013-01-15 2017-01-20 Karl Alex MÜLLER 利用紫外线辐射的氧化物的快速固态反应
KR20160016973A (ko) * 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
US9025712B2 (en) 2013-07-30 2015-05-05 Pixart Imaging Inc. Sensor, clock frequency adjusting system and method thereof
JP6586098B2 (ja) * 2014-02-14 2019-10-02 レスピバート・リミテツド キナーゼ阻害剤としてのピラゾリル尿素
GB201417168D0 (en) 2014-09-29 2014-11-12 Univ Hertfordshire Higher Education Corp Compounds
JP2017538676A (ja) * 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
EP3474835B1 (en) 2016-06-23 2023-07-05 University of Maryland, Baltimore Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
TW201829381A (zh) 2016-12-22 2018-08-16 美商拜奧馬林製藥公司 組蛋白脫乙醯基酶抑制劑
EP3890733B1 (en) 2018-12-07 2025-04-16 University of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021183970A1 (en) 2020-03-13 2021-09-16 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021236449A1 (en) 2020-05-18 2021-11-25 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066616A1 (en) * 2005-03-29 2007-03-22 Paul Shapiro Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor

Also Published As

Publication number Publication date
US20230201211A1 (en) 2023-06-29
US20190151324A1 (en) 2019-05-23
EP3474835B1 (en) 2023-07-05
US20240366619A1 (en) 2024-11-07
EP3474835C0 (en) 2023-07-05
US11357781B2 (en) 2022-06-14
AU2017281222A1 (en) 2019-01-24
US20210267987A1 (en) 2021-09-02
US11911393B2 (en) 2024-02-27
AU2024202879B2 (en) 2025-08-14
EP3474835A1 (en) 2019-05-01
JP7013453B2 (ja) 2022-01-31
US20220331329A1 (en) 2022-10-20
JP2019527239A (ja) 2019-09-26
EP3474835A4 (en) 2020-04-29
WO2017223284A1 (en) 2017-12-28
JP7372993B2 (ja) 2023-11-01
AU2025259977A1 (en) 2025-11-20
CN116570594A (zh) 2023-08-11
US11911392B2 (en) 2024-02-27
CN109640970A (zh) 2019-04-16
AU2022218616B2 (en) 2024-02-29
AU2022218616A1 (en) 2022-09-15
CN109640970B (zh) 2023-05-23
AU2024202879A1 (en) 2024-05-23
JP2022046803A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
AU2022263608B2 (en) Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
AU2022218616B2 (en) Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US20230140941A1 (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
HK40060133B (zh) 非atp/催化位点p38丝裂原活化蛋白激酶抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)